We are live on ! Find out more
SLXN

Silexion Therapeutics
SLXN

6 hedge funds and large institutions have $42.5K invested in Silexion Therapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.03% more ownership

Funds ownership: 1.1% → 5.12% (+4%)

9% less capital invested

Capital invested by funds: $46.7K → $42.5K (-$4.24K)

14% less funds holding

Funds holding: 7 → 6 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$92K
2
UBS Group
UBS Group
Switzerland
+$8.2K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$459

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$26.8K
2
TSS
Two Sigma Securities
New York
-$14.9K
3
Jones Financial Companies
Jones Financial Companies
Missouri
-$32

SLXN Hedge Fund Activity: Q2 2026 in Review

6 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q2 2026, worth a combined $42.5K — down 9.1% from $46.7K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SLXN and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $92K. The largest seller was Citadel Advisors, exiting entirely with an estimated $26.8K sold.

  • 6 institutional investors held Silexion Therapeutics (SLXN) as of Q2 2026, down from 7 in Q1 2026.
  • Funds reported $42.5K of Silexion Therapeutics stock for Q2 2026, down 9.1% quarter-over-quarter.
  • 2 funds opened new Silexion Therapeutics positions in Q2 2026 and 3 closed out, a net change of -1 holder.
  • The largest Silexion Therapeutics buyer in Q2 2026 was HRT Financial, an estimated $92K added.
  • The largest Silexion Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $26.8K sold.

Based on aggregated 13F filings for Q2 2026.